Analytical Data
-
基因名
Ins2
- Application
-
别名
Ins-2
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01326
-
表达区间
25-110aa
-
分子量
16.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like growth factor 2 (IGF2) is a crucial protein involved in growth and development, mainly during fetal growth and postnatal development, acting through the IGF signaling pathway. Research on recombinant IGF2 (Ins2) has gained attention in recent years due to its potential therapeutic applications in regenerative medicine and cancer treatment. IGF2 is known to influence cellular processes such as proliferation, differentiation, and apoptosis, making it a significant target for understanding various diseases, including metabolic disorders and cancers. Recombinant production of IGF2 allows for detailed studies of its structure-function relationships, mechanism of action, and interactions with its receptors. Additionally, the ability to produce Ins2 in a controlled and scalable manner opens avenues for exploring its role in tissue engineering and stem cell biology. Given the increasing incidence of conditions linked to IGF signaling dysregulation, such as obesity and type 2 diabetes, research into Ins2 holds promise for developing targeted therapies. Overall, the study of recombinant Ins2 not only deepens our understanding of fundamental biological processes but also paves the way for innovative approaches to treat diseases associated with growth factor signaling pathways.
